Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRANK-101
- Development stage
- Preclinical
- Lead developer
- MindRank
- Modality
- Small Molecules
01
Overview
MRANK-101 is an investigational small-molecule modulator of the Gastric Inhibitory Polypeptide Receptor (GIPR) being developed by MindRank for the treatment of obesity. Currently in the discovery and optimization phase, this candidate leverages MindRank's AI-driven drug discovery platform to target the GIPR pathway, which plays a significant role in glucose homeostasis and lipid metabolism. As a small molecule, MRANK-101 represents a potential oral alternative to the injectable peptide-based GIPR modulators currently used in metabolic disease management. The program is part of MindRank's wholly-owned pipeline of AI-designed therapeutic candidates.
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)
Beyond the preview
Go deeper on MRANK-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRANK-101.